Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 July 2013Website:
http://www.onconova.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 04 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
ONTX Latest News
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Victor Moyo - Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Meena Arora - VP of Global Medical Affairs & Research and Development, Conference Call Participants Edouard Mullarky - Guggenheim Partners Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.
NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023.
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Steve Fruchtman - President and CEO Dr. Victor Moyo - Consultant Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Fred Frullo - Vice President, Regulatory Affairs and Quality Assurance Conference Call Participants Edouard Mullarky - Guggenheim Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman Sarah, excuse me, you are coming in and out and I don't know if other people hear.
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Bruce Mackle - Managing Director, LifeSci Advisors Steven Fruchtman - President and Chief Executive Officer Michael Saunders - Interim Chief Medical Officer Mark Guerin - Chief Operating Officer and Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Life Science Partners Operator Ladies and gentlemen, thank you for standing by.
Onconova Therapeutics, Inc. (ONTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.20 per share a year ago.
What type of business is Onconova Therapeutics?
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
What sector is Onconova Therapeutics in?
Onconova Therapeutics is in the Healthcare sector
What industry is Onconova Therapeutics in?
Onconova Therapeutics is in the Biotechnology industry
What country is Onconova Therapeutics from?
Onconova Therapeutics is headquartered in United States
When did Onconova Therapeutics go public?
Onconova Therapeutics initial public offering (IPO) was on 25 July 2013
What is Onconova Therapeutics website?
https://www.onconova.com
Is Onconova Therapeutics in the S&P 500?
No, Onconova Therapeutics is not included in the S&P 500 index
Is Onconova Therapeutics in the NASDAQ 100?
No, Onconova Therapeutics is not included in the NASDAQ 100 index
Is Onconova Therapeutics in the Dow Jones?
No, Onconova Therapeutics is not included in the Dow Jones index
When does Onconova Therapeutics report earnings?
Next earnings report date is not announced yet